Cost-efficacy Analysis of Domestic and Imported Olanzapine in the Treatment of Schizophrenia
- VernacularTitle:国产与进口奥氮平治疗精神分裂症的成本效益分析
- Author:
Yunfeng CHEN
;
Yuanfen WANG
;
Tianxing QIN
;
Lianzhong ZHANG
;
Xixian GUO
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Olanzapine;
Cost-efficacy analysis
- From:
China Pharmacist
2015;(6):978-980
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the pharmacoeconomics value of domestic olanzapine with imported olanzapine in the treatment of schizophrenia to provide reference for the rational drug use in clinics. Methods:Two hundred patients with schizophrenia were ran-domly divided into group A ( treated with domestic olanzapine ) and group B ( treated with imported olanzapine ) with 100 cases in each. The treatment course was 8 weeks. The patient’ s condition, adverse reactions, social function, quality of life and daily activity in the two groups were evaluated. Meanwhile, cost-efficacy analysis was performed. Results:The scores of PANSS, SDSS, SQLS and ADL after the treatment were all significantly lower than those before the treatment in both groups (P<0. 01). However, there was no significant difference between the two groups (P>0. 05). In the 2nd and 4th weekend after the treatment, the scores of TESS in group A were all significantly higher than those in group B (P<0. 01). The effectiveness of the two groups was similar. The cost in group A was significantly lower than that in group B(P<0. 01). The efficacy-cost ratio in group A was higher than that in group B(P<0. 01). Conclusion:The domestic olanzapine is as effective and safe as imported olanzapine in the treatment of schizophrenia with lower treat-ment cost. Therefore, the pharmacoeconomics value of domestic olanzapine is much better.
